Lexicon announces proposed public offering and concurrent private placement to fund INPEFA launch

LEXICON PHARMACEUTICALS, INC.

FDA approved INPEFA (sotagliflozin) on May 26, 2023 for heart failure and type 2 diabetes with CKD.
Company expects commercial availability by end of June; sales team booked over 5,000 appointments.
Proposed underwritten public offering of common stock; concurrent private placement to Invus affiliate.
Net proceeds to fund commercial launch of INPEFA, R&D, and working capital.
Bookrunners: Citigroup, Jefferies, Piper Sandler; 30-day over-allotment option to underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.